Answers are grounded in this paper and cite their sources.
Case series highlights distinct patterns of optic neuropathy in patients after treatment with immune checkpoint inhibitors, suggesting possibilities for safe reintroduction.
Two distinct patterns of ICI-induced optic neuropathy emerge: papillitis, usually associated with uveitis and Vogt-Koyanagi-Harada syndrome, and optic neuritis, linked to broader immune-related neurological toxicities and poorer outcomes. Our findings suggest that ICIs may be safely reintroduced after full recovery from ICI-related papillitis.
No takes yet. Share an insight, caveat, or question.
Cuzzubbo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: